Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression.

Abstract

In low-grade MALT lymphoma with prominent gastric expression, continuous monochemotherapy may constitute an efficient alternative to gastrectomy, regardless of disease stage.

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

“…19,20 In the current study, we confirmed a similar CR rate (89%) in 9 patients including 3 patients with Stage II 1 /IV low-grade lymphoma. In addition, 2 of 3 (67%) patients with DLBL also showed CR after OMC, although 1 of these 2 CR patients later experienced disease recurrence.…”

“…For OMC, 100 mg/day cyclophosphamide was administered for 6 -12 months. 19,20 For RT, 30 gray (Gy) in 20 fractions (during the course of 4 weeks) was administered to the involved field for low-grade MALT lymphoma, and 40 Gy in 25-27 fractions (5-6 weeks) was administered for MALT lymphoma plus DLBL. [21][22][23] Toxicity of the second-line treatment was graded according to the National Cancer Institute' Common Toxicity Criteria, version 2.0.…”

“…16 -18 In recent years, however, stomach-conserving treatments such as chemotherapy or irradiation have become increasingly popular even for patients with resectable tumors. Although the efficacy of single-agent chemotherapy/oral monochemotherapy (OMC) 19,20 and radiotherapy (RT) [21][22][23] for gastric MALT lymphoma has been described, no previous reports have yet compared these modalities in detail.…”

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

“…Regimens include alkylating agents (chlorambucil or cyclophosphamide), which are commonly used in low-grade lymphomas, purine analogs, rituximab, and occasionally anthracycline-based chemotherapy for younger patients with more aggressive disease. French investigators used continuous oral administration of a single alkylating agent [89]. Twenty-four patients were treated with cyclophosphamide or chlorambucil for 12-24 months.…”

Combination therapy with rituximab and intravenous or oral fludarabine in the first‐line, systemic treatment of patients with extranodal marginal zone B‐cell lymphoma of the mucosa‐associated lymphoid tissue type

“…14,15 Several prospective studies have produced encouraging results with chemotherapy, such as cyclophosphamide, chlorambucil, 2-chorodeoxyadenosine (2CdA), and combinations with fludarabine or other drugs. [16][17][18][19][20][21][22] Rituximab, an anti-CD20 monoclonal antibody, has demonstrated activity in patients with recurrent/refractory gastric MALT lymphoma who underwent anti-HP therapy or who were not eligible for anti-HP therapy. [23][24][25] The combination of rituximab with chemotherapy achieved better results that either option separately, similar to the results observed in follicular or diffuse large B-cell lymphoma and without a significant addition of toxicity.…”